|
Q4 FY2026
As of Mar 31, 2026
|
Q2 FY2026
As of Sep 30, 2025
|
Q1 FY2026
As of Jul 31, 2025
|
Q4 FY2025
As of Apr 30, 2025
|
Q3 FY2025
As of Jan 31, 2025
|
Q2 FY2025
As of Oct 31, 2024
|
Q1 FY2025
As of Jul 31, 2024
|
Q4 FY2024
As of Apr 30, 2024
|
Q3 FY2024
As of Jan 31, 2024
|
Q2 FY2024
As of Oct 31, 2023
|
Q1 FY2024
As of Jul 31, 2023
|
Q4 FY2023
As of Apr 30, 2023
|
Q3 FY2023
As of Jan 31, 2023
|
Q2 FY2023
As of Oct 31, 2022
|
Q1 FY2023
As of Jul 31, 2022
|
Q4 FY2022
As of Apr 30, 2022
|
Q3 FY2022
As of Jan 31, 2022
|
Q2 FY2022
As of Oct 31, 2021
|
Q1 FY2022
As of Jul 31, 2021
|
Q4 FY2021
As of Apr 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Marketable securities | ||||||||||||||||||||
| Accounts receivable, net | ||||||||||||||||||||
| Inventory | ||||||||||||||||||||
| Research and development tax credit receivable | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Right of use assets | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and stockholders deficit | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued expenses and other current liabilities | ||||||||||||||||||||
| Deferred revenue - current portion | ||||||||||||||||||||
| Lease liability - current portion | ||||||||||||||||||||
| Royalty obligation - current portion | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Long-term liabilities: | ||||||||||||||||||||
| Deferred revenue - net of current portion | ||||||||||||||||||||
| Lease liability - net of current portion | ||||||||||||||||||||
| Deferred royalty obligation | ||||||||||||||||||||
| Royalty obligation | ||||||||||||||||||||
| Total long-term liabilities | ||||||||||||||||||||
| Royalty obligation - net of current portion | ||||||||||||||||||||
| Convertible notes | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders' deficit: | ||||||||||||||||||||
| Common stock, $0.001 par value; 100,000,000 shares authorized at March 31, 2026 and December 31, 2025; 51,237,509 and 50,900,777 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total stockholders' deficit | ||||||||||||||||||||
| Total liabilities and stockholders' deficit |
Loading...
